Literature DB >> 19625887

Gabapentin-induced delirium and dependence.

Stefan P Kruszewski1, Richard P Paczynski, David A Kahn.   

Abstract

Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia. Despite lack of strong evidence, gabapentin is also often prescribed off-label for psychiatric conditions. The case described here involved a 38-year-old male physician with substance intoxication delirium and psychoactive substance dependence due to high self-administered doses of gabapentin, which had been prescribed at lower doses in combination with buspirone and bupropion for depression and anxiety. This unusual case of gabapentin dependence and abuse involved toxic delirium, intense cravings, and a prolonged post-withdrawal confusional state reminiscent of benzodiazepine withdrawal. Gabapentin is a central nervous system inhibitory agent with likely gamma-aminobutyric acid (GABA)-ergic and non-GABAergic mechanisms of action. The similarity between benzodiazepine withdrawal and what this patient experienced with gabapentin suggests a common role for GABA-related effects. The case reported here suggests the need for heightened concern regarding the off-label prescription of this drug to vulnerable individuals with psychiatric conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625887     DOI: 10.1097/01.pra.0000358318.73684.df

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  17 in total

Review 1.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 2.  Misuse and abuse of pregabalin and gabapentin: cause for concern?

Authors:  Fabrizio Schifano
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

3.  Abuse of combinations of gabapentin and quetiapine.

Authors:  Roy R Reeves; Randy S Burke
Journal:  Prim Care Companion CNS Disord       Date:  2014-09-11

4.  Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications.

Authors:  Arton Baftiu; Cecilie Johannessen Landmark; Ida Rudberg Rusten; Silje Andrea Feet; Svein I Johannessen; Pål G Larsson
Journal:  Eur J Clin Pharmacol       Date:  2016-07-13       Impact factor: 2.953

5.  A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.

Authors:  Rachel Vickers Smith; Elaine M Boland; April M Young; Michelle R Lofwall; Alexa Quiroz; Michele Staton; Jennifer R Havens
Journal:  Psychol Addict Behav       Date:  2017-12-14

6.  Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.

Authors:  Nichole C Sanders; Michael J Mancino; W Brooks Gentry; J Benjamin Guise; Warren K Bickel; Jeff Thostenson; Alison H Oliveto
Journal:  Exp Clin Psychopharmacol       Date:  2013-07-15       Impact factor: 3.157

7.  Reversible delirium in an advanced cancer patient.

Authors:  Katharina A Kierner; Christian Jagsch; Herbert H Watzke
Journal:  Wien Med Wochenschr       Date:  2012-01

Review 8.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

Review 9.  Gabapentin misuse, abuse and diversion: a systematic review.

Authors:  Rachel V Smith; Jennifer R Havens; Sharon L Walsh
Journal:  Addiction       Date:  2016-03-18       Impact factor: 6.526

10.  Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification.

Authors:  Michael D Stein; Shannon R Kenney; Bradley J Anderson; Micah T Conti; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2019-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.